Suven Life Sciences Ltd

Suven Life Sciences Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (INR)50.55
  • Today's Change2.50 / 5.20%
  • Shares traded368.49k
  • 1 Year change-33.10%
  • Beta1.9135
Data delayed at least 15 minutes, as of Mar 21 2023 10:29 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Suven Life Sciences Limited is a pharmaceutical company engaged in the business of manufacture and sale of bulk drugs and intermediaries. The Company is focused on discovering and developing new chemical entities (NCEs), which are central nervous system therapies for the treatment of cognitive disorders, depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastrointestinal motility disorders. Its research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal and P2X purinoceptor 7 receptor. It provides a range of Drug Discovery and Development Support Services (DDDSS). The Company offers research services specializing in synthetic, medicinal and analytical chemistry, in-vitro assay development and screening, drug metabolism and pharmacokinetics, toxicology and safety pharmacology, bioanalysis, and NCE formulations.

  • Revenue in INR (TTM)151.49m
  • Net income in INR-1.11bn
  • Incorporated1989
  • Employees117.00
  • Location
    Suven Life Sciences LtdSDE Serene Chambers 6th FloorRoad No. 5 Avenue 7, Banjara HillsHYDERABAD 500034IndiaIND
  • Phone+91 4 023541142
  • Fax+91 4 023541152
  • Websitehttp://www.suven.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Lincoln Pharmaceuticals Ltd5.00bn713.61m6.83bn1.25k9.57--8.531.3735.6235.62249.77------------13.45--17.0852.3750.5514.2613.25--56.07----11.305.2611.4619.7920.914.56
Medico Remedies Ltd-100.00bn-100.00bn6.94bn----------------------------3.41--7.20--24.67--2.43---------1.1217.3388.6824.60-4.35--
Zota Health Care Ltd1.34bn-41.49m7.40bn297.00----134.175.50-1.65-1.6553.61--------4,526,751.00--5.37--7.0536.4830.73-3.094.88---1.62--67.6322.8512.884,364.059.9611.070.9805
Jagsonpal Pharmaceuticals Ltd2.25bn204.13m7.69bn--37.70--35.323.427.797.7985.90------------5.39--6.8560.3658.229.084.60--98.92--38.8515.778.4410.549.71-28.93109.13
NGL Fine-Chem Ltd2.82bn-817.29m7.77bn329.00------2.75-132.29-132.29457.23--------8,580,666.00--17.96--24.1813.7748.76-28.9514.83---63.53--2.9323.0824.42-12.0327.3722.93--
Medicamen Biotech Ltd1.25bn137.00m7.83bn357.0056.22--39.216.2711.0111.01100.53--------3,500,164.00--8.02--11.9751.2233.6610.9710.62--6.12--9.012.426.9622.8223.6229.990.00
Bliss GVS Pharma Ltd7.34bn871.47m7.88bn750.009.22--6.871.078.218.2169.11--------9,784,959.00--7.11--9.8748.3136.8713.1810.68--16.38--11.7929.5012.91-78.04-6.36-6.52-3.58
Bajaj Healthcare Ltd6.91bn569.04m9.08bn1.05k15.96--11.201.3220.6220.62250.20--------6,564,269.00--11.38--19.7026.4725.658.248.64--4.44----3.4924.14-14.1155.6150.96--
Suven Life Sciences Ltd151.49m-1.11bn10.48bn117.00------69.17-6.67-6.670.9369--------1,294,812.00---9.45---10.9276.6465.15-735.49-19.84---360.85-----12.12-53.49-69.08---8.33--
Themis Medicare Ltd3.54bn584.45m11.03bn1.15k18.90--16.093.1263.4163.41384.11--------3,091,841.00--7.88--13.0366.8659.4616.5110.95------6.3971.0711.78104.1335.4930.56--
RPG Life Sciences Limited4.98bn648.10m11.85bn1.17k18.27--14.772.3839.2039.20301.24--------4,275,708.00--10.28--14.9566.3661.7013.017.69--265.31--27.4313.117.4928.7033.61-15.5827.94
TTK Health Care Ltd7.04bn284.73m12.27bn2.59k43.08--29.271.7420.16448.26498.06--------2,718,869.00--5.08--8.3751.2656.704.053.76--1.52--34.3125.882.57-49.68-0.24633.7214.87
Morepen Laboratories Ltd14.22bn427.58m12.83bn2.38k30.00--18.180.90220.83670.836727.43--------5,980,358.00--8.25--17.0832.7233.953.015.86--24.75--0.0030.2021.044.7333.8946.89--
Solara Active Pharma Sciences Ltd14.24bn-240.60m13.07bn2.25k----14.790.9179-6.69-6.69391.54--------6,317,702.00--------41.68---1.70-----0.1553-----21.56---126.26------
Novartis India Ltd4.01bn549.70m13.75bn81.0025.01--22.813.4322.2622.26162.31--------49,497,530.00--3.13--3.9748.8657.4213.717.18--31.51--75.564.86-9.43-117.80---29.150.00
Data as of Mar 21 2023. Currency figures normalised to Suven Life Sciences Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

0.31%Per cent of shares held by top holders
HolderShares% Held
SSgA Funds Management, Inc.as of 02 Mar 2023654.88k0.30%
Hamon Asset Management Ltd.as of 30 Sep 201921.70k0.01%
Motilal Oswal Asset Management Co. Ltd.as of 28 Feb 2023735.000.00%
Data from 31 Aug 2022 - 28 Feb 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.